Showing results (91-100 of 105) with videos related to

Sort By:
Pageof 11
Human Vaccines & Immunotherapeutics|May 30, 2023
Safety and immunogenicity of rabies vaccine (PVRV-WIBP) in healthy Chinese aged 10-50 years old: Randomized, blinded, parallel controlled phase III clinical studyXiaoyuan Huang, Jing Liang, Lili Huang, et al.
Virologica Sinica|May 8, 2022
Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variantsJia Lu, Qiangling Yin, Rongjuan Pei, et al.
Antiviral Research|June 3, 2023
Development of MDCK-based quadrivalent split seasonal influenza virus vaccine with high safety and immunoprotection: A preclinical studyJiayou Zhang, Xuanxuan Nian, Bo Liu, et al.
Human Vaccines & Immunotherapeutics|June 17, 2022
Clinical evaluation of the lot-to-lot consistency of an enterovirus 71 vaccine in a commercial-scale phase IV clinical trialJinhua Chen, Pengfei Jin, Xiaoqi Chen, et al.
Vaccines|July 27, 2024
The Protective Efficacy of a SARS-CoV-2 Vaccine Candidate B.1.351V against Several Variant Challenges in K18-hACE2 MiceJie Yang, Huifen Fan, Anna Yang, et al.
Cell Discovery|September 8, 2022
Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineagesXiaoman Li, Yongbing Pan, Qiangling Yin, et al.
Eclinicalmedicine|August 4, 2022
Immunogenicity and safety of an enterovirus 71 vaccine in children aged 36-71 months: A double-blind, randomised, similar vaccine-controlled, non-inferiority phase III trialYeqing Tong, Xinyue Zhang, Jinhua Chen, et al.
Antiviral Research|March 5, 2023
Heterologous boost with mRNA vaccines against SARS-CoV-2 Delta/Omicron variants following an inactivated whole-virus vaccineChangrui Lu, Yuntao Zhang, Xiaohu Liu, et al.
JAMA|August 14, 2020
Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical TrialsShengli Xia, Kai Duan, Yuntao Zhang, et al.
Frontiers in Immunology|July 11, 2022
Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 TrialShengli Xia, Kai Duan, Yuntao Zhang, et al.
Pageof 11